Pyoderma Gangrenosum

InflaRx has initiated a phase 3 study of vilobelimab in patients with ulcerative pyoderma gangrenosum, the company announced in a press release.

Pain as a patient-reported outcome measure during the treatment of pyoderma gangrenosum may indicate whether a patient is responding to treatment, according to a research letter published in JAMA Dermatology.

Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with the general population, according to a cohort study.